Clinical Trial Update: Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating cetuximab and envafolimab in combination with mFOLFOXIRI as first-line treatment for RAS/BRAF wild-type, MSS, unresectable left-si…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Cetuximab (cetuximab)
• Envafolimab (envafolimab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: RECRUITING